This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of osteosarcoma and malignant fibrous histiocytoma of bone. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
The Gerson therapy is a complex regimen that has been used to treat people with cancer and other diseases (see Question 1).
The key parts of the Gerson therapy are a strict diet, dietary supplements, and enemas (see Question 1).
The theory is that disease can be cured by removing toxins from the body, boosting the immune system, and replacing excess salt in the body's cells with potassium (see Question 3).
The Gerson therapy requires that the many details of its treatment plan be followed...
This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
be discussed at a meeting,
be cited with text, or
replace or update an existing article that is already cited.
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
The lead reviewers for Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment are:
Holcombe Edwin Grier, MD (Dana-Farber Cancer Institute/Boston Children's Hospital)
Karen Jean Marcus, MD (Dana-Farber Cancer Institute/Boston Children's Hospital)
Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)
Thomas A. Olson, MD (AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus)
Nita Louise Seibel, MD (National Cancer Institute)
Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.